申请人:AstraZeneca AB
公开号:EP2275139A1
公开(公告)日:2011-01-19
An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of a capsule dosage form. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.
一种口服药物剂型,包含一种易受酸影响的质子泵抑制剂和一种或多种非甾体抗炎药的固定制剂,其中质子泵抑制剂由肠溶包衣层保护。固定制剂为胶囊剂型。新的固定制剂尤其适用于治疗与非甾类抗炎药治疗相关的胃肠道副作用。